ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1668

Long-Term Outcomes in Children Born to Anti-Ro and/or Anti-La Positive Mothers

Talia Diaz1, Daniela Dominguez2, Edgar Jaeggi3, Andrea Knight4, Carl A. Laskin5, Lawrence Ng6, Franklin Silverio1, Earl D. Silverman7 and Linda Hiraki8, 1Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, 2Division of Rheumatology, The Hospital for Sick Children, Toronto, Canada, 3Fetal Cardiac Program, The Hospital for Sick Children, Toronto, ON, Canada, 4Division of Rheumatology, The Hospital for Sick Children and Department of Paediatrics, University of Toronto, Toronto, ON, Canada, 5Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada, 6Division of Rheumatology, Hospital for Sick Children, Toronto, Canada, 7Division of Rheumatology, The Hospital for Sick Children, Translational Medicine, Research Institute, The Hospital for Sick Children, and Department of Paediatrics, University of Toronto., Toronto, ON, Canada, 8Division of Rheumatology, The Hospital for Sick Children, Child Health Evaluative Sciences, Research Institute, The Hospital for Sick Children, and Department of Paediatrics, University of Toronto., Toronto, ON, Canada

Meeting: ACR Convergence 2020

Keywords: Autoantibody(ies), Cohort Study, Outcome measures, Pediatric rheumatology

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2020

Title: Pediatric Rheumatology – Clinical Poster III: SLE, Vasculitis, & JDM

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: Neonatal Lupus Erythematosus (NLE) is an acquired autoimmune disorder associated with the transplacental passage of maternal anti-Ro and/or anti-La antibodies. Previous studies have suggested that children born to anti-Ro/La antibody positive mothers with a rheumatic disease, might be at greater risk of developing autoimmune and non-autoimmune diseases, as children or young adults. The aim of this study was to determine the prevalence of autoimmune and non-autoimmune diseases in children born to anti-Ro/La positive mothers.

Methods: We conducted a cohort study of infants seen in the NLE clinic at SickKids Hospital between 1987-2019. Infants born to anti-Ro/La antibody positive mothers in the Greater Toronto Area were referred to the NLE clinic. Surveys were sent to those children discharged from the NLE clinic and consented to this study. We invited parents of patients ≥ 1y and < 18 years of age, and patients >18 y of age to complete a follow-up questionnaire via REDCap survey link. The survey included questions about autoimmune diseases such as rheumatic diseases (arthritis, connective tissue disease, vasculitis) and non-rheumatic diseases (psoriasis, thyroid disease, inflammatory bowel disease, type I diabetes),  and non-autoimmune diseases such as allergic (seasonal allergies, anaphylaxis, asthma, eczema, urticaria), neurodevelopmental (autism, attention deficit hyperactivity disorder, global developmental delay), and neuropsychiatric diagnoses (anxiety, depression, tics, seizures, obsessive-compulsive disorder). NLE manifestations and maternal disease status during pregnancy were obtained from a dedicated database prospectively collected. Descriptive statistics were used for demographic characteristics and clinical features of NLE. Prevalence of autoimmune and non-autoimmune diseases were compared using Fisher’s exact test.

Results: We sent 354 surveys with a completion rate of 61% (n=217). Eight patients were excluded due to unconfirmed antibody status during pregnancy. We included 209 children born to 166 unique mothers. Median age at questionnaire completion was 6 years (IQR: 3,11), 50% female (Table 1). Forty-seven percent (n=96) of the children had NLE, and 67% (n=141) of the children were born to a woman with a rheumatic disease diagnosis during pregnancy. In our cohort, allergic diseases were the most frequent reported at 28% (n=59) and only 6 patients (3%) had developed autoimmune diseases. There was no difference in the prevalence of reported diseases/conditions between children born to a mother with or without rheumatic disease (Table 2).

Conclusion: In our multiethnic population of children born to women with positive anti-Ro and/or anti-La antibodies, there was no significant difference in the prevalence of autoimmune and non-autoimmune diseases between children with and without NLE manifestations, or born to women with and without a rheumatic disease during pregnancy. This is one of the largest cohort studies investigating long-term outcomes in this population. Continued recruitment of older participants will improve our ability to detect diseases with onset in young adulthood.

Table 1: Characteristics of children born to women with positive anti-Ro and/or anti-La antibodies (n=209)

Table 2: Reported Disease Diagnosis of Children Born to Women with and without a Rheumatic Disease Status during Pregnancy (n=209)


Disclosure: T. Diaz, None; D. Dominguez, None; E. Jaeggi, None; A. Knight, None; C. Laskin, None; L. Ng, None; F. Silverio, None; E. Silverman, None; L. Hiraki, None.

To cite this abstract in AMA style:

Diaz T, Dominguez D, Jaeggi E, Knight A, Laskin C, Ng L, Silverio F, Silverman E, Hiraki L. Long-Term Outcomes in Children Born to Anti-Ro and/or Anti-La Positive Mothers [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/long-term-outcomes-in-children-born-to-anti-ro-and-or-anti-la-positive-mothers-2/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/long-term-outcomes-in-children-born-to-anti-ro-and-or-anti-la-positive-mothers-2/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology